
Join to view full profile
420 Delaware St SESte MMC284Minneapolis, MN 55455
Phone+1 612-626-5031
Dr. Zorko is on Doximity
As a Doximity member, you’ll join more than three million U.S. healthcare professionals—including 85+% of physicians, and 2/3 of all NPs and PAs—in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Nicholas Zorko is a hematologist in Minneapolis, MN and is affiliated with multiple hospitals in the area, including M Health Fairview University of Minnesota Medical Center and Minneapolis VA Medical Center. He received his medical degree from Ohio State University College of Medicine and has been in practice 1 year. He has more than 10 publications and over 400 citings.
Education & Training
University of MinnesotaResidency, Internal Medicine, 2015 - 2021
Ohio State University College of MedicineClass of 2015
Certifications & Licensure
MN State Medical License 2016 - 2026
American Board of Internal Medicine Internal Medicine
American Board of Internal Medicine Hematology
American Board of Internal Medicine Medical Oncology
Publications & Presentations
PubMed
- B7-H3 Gene Expression Shapes Prognosis and Therapeutic Opportunities across Patient Groups with Prostate Cancer.Allison Makovec, Ava P Gustafson, Nishant Gandhi, Swati Rampalli, Ali T Arafa
Clinical Cancer Research. 2026-08-03 - Case of complete response to immunotherapy in MMR-deficient prostate cancer associated with NK-like and CD4CD8T cells.Alexander K Tsai, John R Lozada, Philippa R Kennedy, David Moline, Rachana Pandey
Cell Reports. Medicine. 2026-07-21 - iPSC-derived NK cell therapy induces durable responses in glioblastoma and overcomes resistance via a B7-H3-targeted tri-specific killer engager.Jian-Fang Ning, Zachary B Davis, Qudsia Zeb, Peter Hinderlie, Katie Tuininga
Neuro-Oncology. 2026-07-11
Press Mentions
‘Cold’ Solid Tumors Become the Proving Ground for a New Generation of Engager and Immune-Priming TherapiesMay 15th, 2026
Professional Memberships
- Member
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:









